BioCryst Pharmaceuticals

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$117,085
$109,332
$92,761
$93,401
Gross Profit
113,857
107,278
91,496
91,341
EBITDA
11,692
9,081
-10,202
-38,156
EBIT
11,381
8,761
-10,508
-38,579
Net Income
-14,033
-12,674
-35,379
-61,731
Net Change In Cash
117,085
109,332
92,761
93,401
Free Cash Flow
9,037
-1,925
-53,919
-9,472
Cash
97,654
80,205
84,333
112,447
Basic Shares
206,905
206,425
206,064
201,409

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$331,412
$270,827
$157,170
$17,812
Gross Profit
326,751
264,233
149,906
16,136
EBITDA
-116,335
-143,854
-121,738
-167,565
EBIT
-117,990
-145,291
-122,515
-168,313
Net Income
-226,539
-247,117
-184,062
-196,567
Net Change In Cash
331,412
270,827
157,170
17,812
Cost of Revenue
233,386
158,625
Free Cash Flow
-97,309
-163,201
-144,542
-137,730
Cash
110,643
304,767
504,389
272,127
Basic Shares
192,198
185,908
179,117
167,267

Earnings Calls

Quarter EPS
2024-09-30
-$0.07
2024-06-30
-$0.06
2024-03-31
-$0.17
2023-12-31
-$0.28